CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 96 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q3 2020. The put-call ratio across all filers is 0.41 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2021 | $1,616,000 | +5.6% | 78,426 | -10.2% | 0.00% | 0.0% |
Q4 2020 | $1,530,000 | +28.9% | 87,335 | +9.1% | 0.00% | 0.0% |
Q3 2020 | $1,187,000 | +660.9% | 80,026 | +565.4% | 0.00% | – |
Q2 2020 | $156,000 | +680.0% | 12,026 | 0.0% | 0.00% | – |
Q1 2020 | $20,000 | -25.9% | 12,026 | 0.0% | 0.00% | – |
Q4 2019 | $27,000 | +3.8% | 12,026 | 0.0% | 0.00% | – |
Q3 2019 | $26,000 | -18.8% | 12,026 | 0.0% | 0.00% | – |
Q2 2019 | $32,000 | -45.8% | 12,026 | 0.0% | 0.00% | – |
Q1 2019 | $59,000 | – | 12,026 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Kynam Capital Management, LP | 3,388,967 | $125,425,669 | 9.68% |
5AM Venture Management, LLC | 497,270 | $18,403,963 | 4.12% |
COMMODORE CAPITAL LP | 1,425,000 | $52,739,250 | 3.60% |
SILVERARC CAPITAL MANAGEMENT, LLC | 374,910 | $13,875,419 | 3.27% |
TSP Capital Management Group, LLC | 249,220 | $9,223,635 | 2.89% |
Eventide Asset Management | 3,327,132 | $123,137,155 | 2.11% |
Affinity Asset Advisors, LLC | 475,400 | $17,594,554 | 2.03% |
Novo Holdings A/S | 850,000 | $31,458,500 | 1.83% |
Bellevue Group AG | 2,971,615 | $109,979,471 | 1.79% |
Redmile Group, LLC | 718,723 | $26,599,938 | 1.61% |